Therapeutic Effects of Topical 8-Oxo-2'-deoxyguanosine on Ethanol-Induced Ocular Chemical Injury Models
Overview
Authors
Affiliations
Purpose: To evaluate the therapeutic effects of topical 8-oxo-2'-deoxyguanosine (8-oxo-dG) on experimental ocular chemical injury models.
Methods: We created ocular chemical injury models with 8-week-old BALB/c mice (n = 70) by applying 100% ethanol; the mice were then treated with 8-oxo-dG eye drops 10 and 5 mg/mL and phosphate-buffered saline (PBS) twice daily. After 7 days, clinical findings such as corneal integrity, clarity, and neovascularization were assessed. Histology, immunohistochemistry findings, and inflammatory cytokine levels using real-time polymerase chain reactions in the corneas of the mice were also analyzed.
Results: Topical application of 8-oxo-dG eye drops resulted in a significant improvement of epithelial defects and clarity, dose dependently (each P < 0.001). Inflammatory cell infiltration and corneal stromal edema were also decreased in the 8-oxo-dG-treated mice compared with PBS-treated controls, based on hematoxylin and eosin staining. The expressions of F4/80 and neutrophil elastase-positive inflammatory cells and IL-1 and TNF-α cytokine levels were significantly reduced in the 8-oxo-dG group compared with the PBS group (each P < 0.01).
Conclusions: Topical 8-oxo-dG application showed an excellent therapeutic effect in ocular chemical injury models by suppressing inflammation.
Efficacy of RCI001 as a Therapeutic Candidate in a Primary Sjögren Syndrome Mouse Model.
Kang H, Jung Y, Moon J, Ryu J, Yoon C, Kim Y Cornea. 2024; 44(2):226-233.
PMID: 39288434 PMC: 11676593. DOI: 10.1097/ICO.0000000000003696.
Efficacy of RCI001 as a therapeutic candidate of dry eye disease in a modified mixed dry eye model.
Jung Y, Ku Y, Moon J, Kim S, Ryu J, Yoon C Eye Vis (Lond). 2024; 11(1):19.
PMID: 38822444 PMC: 11143567. DOI: 10.1186/s40662-024-00388-z.
Comparison of RCI001 and corticosteroid on the effects on intraocular pressure in mice.
Kim S, Ku Y, Yoo C, Kim Y, Kim D Front Med (Lausanne). 2023; 10:1256569.
PMID: 37877019 PMC: 10591319. DOI: 10.3389/fmed.2023.1256569.
Song M, Ku Y, Kim S, Chung M, Kim Y, Kim D Korean J Ophthalmol. 2023; 37(3):236-244.
PMID: 37309557 PMC: 10270771. DOI: 10.3341/kjo.2023.0019.
Ji M, Son K, Hong J Antioxidants (Basel). 2022; 11(9).
PMID: 36139714 PMC: 9495749. DOI: 10.3390/antiox11091641.